It's more than a test.

It's more accurately identifying your patients’ risk of a future cardiac event.

Using cardiovascular risk stratification to identify the risk of future cardiac events in the asymptomatic population is key to ensuring the right patients receive appropriate care in a timely manner.1

Couple banner image
Couple banner image
Couple banner image

Alinity i and ARCHITECT STAT High Sensitive Troponin-I

Abbott's STAT High Sensitive Troponin-I blood test can help to identify patients at elevated-risk or potentially at elevated-risk of a future cardiac event, heart failure or cardiovascular disease (CVD), including cardiovascular (CV) death, myocardial infarction (MI), coronary revascularization, or ischemic stroke. The result, in conjunction with clinical and diagnostic findings, can then be used to prioritize the care of at-risk patients, helping to deliver more individualized and proactive patient care that helps to mitigate the risk of unfavourable cardiac outcomes.2,3 Because behind every test there is a real life at stake.

Troponin I is specific to the heart and therefore it can help to more accurately categorize patients' risk, in conjunction with other clinical and diagnostic findings, before they experience a CV event.1–3


There are a variety of CV risk prediction models currently available, however no other test is specific to the heart. These other models, which take into consideration the presence of CV risk factors, are indirect methods that pose challenges due to their:4,5

  • focus on age
  • applicability only in certain populations
  • ability to measure a limited number of CV outcomes.4,5

STAT High Sensitive Troponin-I – Early cardiac risk stratification model

STAT High Sensitive Troponin-I from Abbott can detect troponin, which is released when the heart muscle is injured, even at low levels. Using the results from an STAT High Sensitive Troponin-I blood test can help you to more accurately stratify the risk of a future cardiac event in an asymptomatic individual into one of three categories:2,3

In conjunction with clinical and diagnostic findings, it enables you to better prioritize appropriate care for those at higher risk to help prevent adverse outcomes, and potentially avoid unnecessary investigations and treatments in those at lower risk. 

Through this early cardiac risk identification model, long-term lifestyle changes and targeted treatments can be recommended to patients before a cardiac event takes place.6  This helps you to empower patients to take control of their well-being by making healthy choices.



High-sensitive background image
High-sensitive background image

WHAT DO STAT High Sensitive Troponin-I

STAT High Sensitive Troponin-I results are to be applied to the risk stratification table shown below:

The following cut-off points may be used to aid in stratifying the risk of CVD in
asymptomatic individuals:2,3,7

In conjunction with clinical and diagnostic findings, sex-specific thresholds enable clinicians to appropriately stratify an individual’s risk of a future cardiac event and prioritize the right preventative measures for each person to help improve their cardiac health.

Find out more about
how Abbott's STAT High Sensitive Troponin-I can more accurately predict the risk of a future cardiac event even in an apparently healthy population.




It's more than a test.

Assess which risk category (low/moderate/elevated) an individual falls into based on the corresponding troponin I level. An accompanying statement interpreting these results may be provided.

Use your clinical judgement and adhere to recommended cardiovascular prevention guidelines to determine the standard of care appropriate for your patient based upon their level of risk.

Motivate your patients to take action to make healthier living choices to improve their heart health.

A cardiac-specific risk assessment tool that more accurately predicts future CV events

Hear first-hand experiences

Listen to Prof. Goran Krstačić and his patient, Stanislava Kubat, share their experiences with the use of STAT High Sensitive Troponin-I for cardiovascular risk stratification. 

Goran Krstačić
Director of Institute for Cardiovascular Prevention and Rehabilitation, Zagreb, Croatia


Stanislava Kubat
Patient, treated by Goran Krstačić

Troponin as the direct signal coming from the heart

Learn the differences between traditional cardiac risk factors and troponin.

Cardiac risk stratification with Abbott's STAT High Sensitive Troponin-I versus other current tools

Current risk-stratification tools such as Framingham, SCORE, and Lipid profile are not cardiac-specific and can be overly influenced by age. Abbott's STAT High Sensitive Troponin-I risk stratification blood test contains the protein troponin I, which is specific to the heart. This means it can more accurately categorize patients' risk when used in conjunction with clinical and diagnostic findings.6,8–11

Early detection to more accurately evaluate risk of future cardiac events, in conjunction with other clinical and diagnostic findings.6

Greater accuracy in identifying lower-risk patients, which may avoid unnecessary testing, treatments, and potential side effects.6

Potential to reduce the growing cost burden to the health care system by appropriately recategorizing at-risk patients.6

STAT High Sensitive Troponin-I is not impacted by biotin interference.12

Troponin customer experience

Troponin – A mirror of cardiac health?

Cardiologists Professor Dr. Christoph Liebetrau and Associate Professor Dr. Till Keller from the Cardiac Center in Bad Nauheim, Germany discuss the significance of cardiac risk stratification with troponin I and possible areas of application.

Risk-satisfaction background image
Risk-satisfaction background image


The journey towards better CV outcomes in asymptomatic individuals should begin with a more accurate risk assessment, in conjunction with clinical and diagnostic findings. Incorporate STAT High Sensitive Troponin-I, a cardiac specific blood test from Abbott, into to your patients' health checks.

predict background image
predict background image


Understand the Value of Troponin

Explore how STAT High Sensitive Troponin-I may enable easier management of patients with suspected AMI.

Cardiac Assays

Instill confidence in your cardiac care decision making with our comprehensive cardiac assay menu.

Visit the Knowledge Center

Find the latest information in laboratory science, therapeutic areas and Abbott innovation.

  1. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation. 2012;126(16):2020–35.
  2. ARCHITECT STAT High Sensitive Troponin-I [package insert]. Lake Bluff, IL: Abbott Laboratories; September 2021. G97079R02.
  3. Alinity i STAT High Sensitive Troponin-I [package insert]. Lake Bluff, IL: Abbott Laboratories; September 2021. H05938R04.
  4. DeFilippis AP, Young R, Carrubba CJ et al. Ann Intern Med. 2015 Feb 17;162(4):266–75.
  5. Garg P, Muduli SK, Kapoor A, et al. Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses. Indian Heart J. 2017;69(4):458–63. doi:10.1016/j.ihj.2017.01.015.
  6. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81.
  7. Sigurdardottir FD, Lyngbakken MN, Holmen OL, et al. Relative prognostic value of cardiac troponin I and C-reactive protein in the general population (from the Nord-Trøndelag Health [HUNT] Study). Am J Cardiol. 2018;121(8):949–55. 
  1. Ford I, Shah ASV, Zhang R, et al. High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease. J Am Coll Cardiol. 2016;68(25):2719–28. doi:10.1016/j.jacc.2016.10.020.
  2. Blankenberg S, Salomaa V, Makarova N, et al. Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. Eur Heart J. 2016;37(30):24–37. doi:10.1093/eurheartj/ehw172.
  3. Everett BM, Zeller T, Glynn RJ, Ridker PM, Blankenberg S. High-sensitivity cardiac troponin I and B-type natriuretic peptide as predictors of vascular events in primary prevention: impact of statin therapy. Circulation. 2015;131(21):18–60. doi:10.1161/CIRCULATIONAHA.114.014522.
  4. Omland T, Lemos de, JA, Holmen OL et al. Impact of Sex on the Prognostic Value of High-Sensitivity Cardiac Troponin I in the General Population: The HUNT Study, Clin Chem. 2015 Apr;61(4):646–56.
  5. Trambas C, Lu Z, Yen T et al. Depletion of biotin using streptavidin-coated microparticles: a validated solution to the problem of biotin interference in streptavidin–biotin immunoassays. Ann Clin Biochem. 2017;55(2):216–26.